Sermo Reports Jury Is Still Out on Remdesivir; 31% of Physicians Who Have Used Remdesivir Rate It as Highly Effective; 31% Rate It with Low Effectiveness; 38% Rate It as Somewhere in the Middle

In the past, we have scaled up antibodies by producing them in sheep and horses, so it would be interesting to look into monoclonal antibodies.